51 results about "Tyrosine Kinase 3" patented technology

Disclosed herein is a system and method for producing T cells from stem cell populations. Specifically exemplified herein is a culture system and method that produces CD4 cells and/or T cell subtypes from a CD4 lineage using a sample of hematopoietic stem cells. Adult hematopoietic precursor/stem cells (HPC) are progenitors to all lineages of immune cells. There has been limited success in generating functional CD4 T cells with this convenient culture system. Also disclosed herein is a novel stromal cell line expressing DL1, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (Flt3-L). This improved culture system can greatly facilitate the study of late T cell development and enables immunotherapeutic applications.

The invention relates to a compound for inhibiting the activity of BTK (Bruton's Tyrosine Kinase) and/or JAK3 (Janus Tyrosine Kinase 3), a medicinal composition of the compound, a use of the compound in the pharmacy, a method for inhibiting the activity of BTK and/or JAK3 by using the compound, and a method for treating and/or preventing BTK and/or JAK3 mediated diseases or illnesses in mammals (especially human beings) by using the compound. The compound is represented by structural formula I shown in the specification.

The invention belongs to the technical field of organic synthetic medicines, and particularly relates to a substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative, and a preparation methodand use thereof. The substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative has a structural formula shown in Formula I. The invention also provides the preparation method of the substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative and use of the substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative in preparation of FMS-tyrosine kinase 3 inhibitors. A new and effective choice is provided for the preparation of the kinase inhibitors, the preparation of drugs for anti-autoimmune diseases, the preparation of neovascularization inhibitors and anti-tumordrugs in the field, and the substituted 1-(isoxazol-3-yl)-3-(3-fluoro-4-phenyl) urea derivative has a good application prospect.

The invention relates to a stem cell amplifying culture medium and a stem cell culture method. The ingredients of the stem cell amplifying culture medium comprise a basic culture medium, a stem cell factor, thrombopoietin, an FMS like tyrosine kinase 3 ligand and interleukin-6, wherein the final concentration of the stem cell factor is 90ng/mL-110ng/mL, the final concentration of the thrombopoietin is 10ng/mL-30ng/mL, the final concentration of the FMS like tyrosine kinase 3 ligand is 90ng/mL-110ng/mL, and the final concentration of the interleukin-6 is 10ng/mL-30ng/mL. When the stem cell amplifying culture medium is used for culturing cord blood hematopoietic stem cells, obvious cell amplifying effects can be presented, CD34+ on cell surfaces is also notably increased, during cell amplification, the cell state is stable, the multi-directional differentiation capacity is maintained, and the culture medium is an economic efficient culture system.

The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.

Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates tothe use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVA[delta]C7L and VACV[delta]C7L, respectively),alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVA[delta]C7L or VACV[delta]C7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

The embodiment relates to modified cells for treating a solid tumor, a composition and a method. For example, the composition comprises inducible Fms-like tyrosine kinase 3 ligand (FLT3L) modified cells; the modified cells comprise separated polynucleotide; and the separated polynucleotide comprises polynucleotide of coded FLT3L and polynucleotide of a coded Nuclear Factor of Activated T cells (NFAT) promoter, which is operably connected.

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

The invention relates to the field of medicinal chemistry, discloses an indole substituted azole compound and applications thereof, and specifically relates to an indole substituted azole compound anda preparation method thereof, a pharmaceutical composition containing the indole substituted azole compound, and medical applications of the indole substituted azole compound and the pharmaceutical composition, especially applications as FMS-like tyrosine kinase 3 inhibitors.

The invention relates to the field of medicinal chemistry, and discloses a benzimidazole substituted azole compound and applications thereof, and specifically relates to a benzimidazole substituted azole compound and a preparation method thereof, a pharmaceutical composition containing the benzimidazole substituted azole compound, medical applications of the benzimidazole substituted azole compound and the pharmaceutical composition, and especially applications as FMS-like tyrosine kinase 3 inhibitors.

The present invention relates to a method of safely and simply inducing differentiation of mononuclear cells into cells that promote neovascular stabilization and maturation, and lead to recovering from ischemia or tissue repair. The cells according to the present invention are obtained by inducing differentiation of a mononuclear cell by culturing the mononuclear cell in a medium (particularly a serum-free medium) containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), and collecting a cell population expressing CD11b.

The invention belongs to the field of traditional Chinese medicine detection and particularly relates to a serum-free culture medium capable of proliferating hematopoietic stem cells and a preparationmethod of the culture medium. The provided serum-free culture medium capable of proliferating hematopoietic stem cells comprises stephanine, berberine, bFGF, aFGF, IGF1, IGF2, transferrin, insulin growth factors, EGF, interleukin 1, interleukin 2, interleukin 6, stem cell factors, thrombopoietin, fMS-like tyrosine kinase 3 ligands and a DMEM/F12 culture medium. By adding stephanine and berberine,the serum-free culture medium not only has the capability of proliferating the hematopoietic stem cells derived from placentae, bone marrow and peripheral blood in vitro, improving the adherence capability of the hematopoietic stem cells and increasing the cell proliferation rate of the hematopoietic stem cells but also can maintain the self-renewal capability and multidirectional differentiationcapability of the stem cells. The hematopoietic stem cells proliferated by the serum-free culture medium have a good effect of promoting the reconstruction of a hematopoietic system in the body of apatient.

The present invention discloses a culture system used for umbilical cord blood hematopoiesis stem cell amplification and application thereof, the culture system includes an AIM-V culture medium, platelet lysate PL, stem cell factor SCF, human FMS-like tyrosine kinase 3 ligand Flt-3L , G-CSF and IL-3, and angiopoietin-likeprotein 3 (ANGPTL3), small molecule compound StemRegenin (SR1) and pyrimidine-indole molecule UM171 are also added. By adding of the appropriate concentration of ANGPTL3, SR1 and UM171 for combination, the number of hematopoiesis stem cell population is greatly increased, the culture system is used for umbilical cord blood hematopoiesis stem cell growth and amplification, to be more important, implantation capacity and hematopoietic system reconstruction capacity after hematopoietic stem cells are transplanted into a receptor are significantly improved, and the culture system opens up new use prospects in clinical amplification of umbilical cord blood stem cells.

An in vitro culture method for inducing human umbilical cord blood cells CD34+ to differentiate into Langerhans cell includes culturing human umbilical cord blood cells CD34+ in a medium containing GM-CSF (granulocyte-macrophage colony stimulating factor), TNF-alpha (tumor necrosis factor-alpha), SCF (stem cell factor) and Flt3L (FMS-like tyrosine kinase 3 ligand), and differentiating the human umbilical cord blood cells CD34+ into Langerhans cells. The Langerhans cells generated are highly pure and high in yield, and have the functions of recognizing, absorbing and processing antigens and the function of activating immune response.

The invention relates to the field of medicinal chemistry, and discloses an oxygen-containing heterocyclic substituted azole compound and applications thereof, and specifically relates to an oxygen-containing heterocyclic substituted azole compound and a preparation method thereof, a pharmaceutical composition containing the oxygen-containing heterocyclic substituted azole compound, and medical applications of the oxygen-containing heterocyclic substituted azole compound and the pharmaceutical composition, particularly applications as FMS-like tyrosine kinase 3 inhibitors.

The present invention relates to a novel benzimidazole derivative having fms-like tyrosine kinase 3 (FLT3) inhibitory activity, and a use thereof. A novel benzimidazole derivative or a pharmaceutically acceptable salt thereof, according to the present invention, exhibits excellent inhibitory activity against FLT3, and thus targeted treatment through more fundamental approaches is expected in the prevention or treatment of acute myeloid leukemia (AML).